Stockreport

Lonza's Synaffix and Sidewinder Therapeutics Announce Multi-Target License Agreement to Advance Development of Next-Generation Bispecific ADCs

LONZA GROUP AG UNSP/ADR  (LZAGY) 
NASDAQ:AMEX Investor Relations: lonza.com/about-lonza/investor-relations.aspx
PDF Multi-target license agreement grants Sidewinder access to Lonza's clinically validated ADC platformSidewinder's pipeline of precision bispecific ADCs combined with Lonz [Read more]